Acid suppression strategies for H. pylori eradication: Tegoprazan vs. PPIs

Summaries 2 min 91

Font Size

Created On: 23/01/2026

Tegoprazan is a next-generation potassium-competitive acid blocker (P-CAB) that delivers rapid and sustained gastric acid suppression.

See All

Key take away

Tegoprazan-based therapy achieves H. pylori elimination rates and patient compliance comparable to PPIs while demonstrating a lower overall incidence of adverse events.

Background

Tegoprazan is a next-generation potassium-competitive acid blocker (P-CAB) that delivers rapid and sustained gastric acid suppression. While proton pump inhibitors (PPIs) remain the standard intervention for Helicobacter pylori (H. pylori) elimination, the comparative effectiveness and safety of tegoprazan-based eradication regimens warrant further evaluation. This meta-analysis explored the clinical outcomes of tegoprazan vs. PPI-based therapies in H. pylori infection.

Method

A systematic literature search was executed across major electronic databases to identify studies comparing H. pylori elimination rates, treatment-related adverse events, and patient compliance between tegoprazan- and PPI-based regimens. Eligible studies were quantitatively analyzed via RevMan version 5.4, with outcomes assessed through intention-to-treat (ITT) and subgroup assessment.

Result

Overall, 8 studies encompassing 4,640 patients met the inclusion criteria. ITT analysis demonstrated comparable H. pylori eradication rates between tegoprazan- and PPI-based therapies, with no difference in treatment compliance. Tegoprazan-based regimens were linked with a markedly lower incidence of adverse events when compared to PPIs, although this benefit was not consistently observed in randomized controlled trials (Table 1).

Subgroup analyses revealed higher elimination success in studies conducted in China, with 10- or 14-day treatment durations, and when dual or bismuth-containing quadruple therapies were used; however, regimen type did not independently impact eradication outcomes.

Conclusion

Tegoprazan-based H. pylori therapy achieved eradication rates, patient adherence, and overall safety profiles comparable to PPI-based regimens, supporting its role as a potent alternative acid-suppressive strategy.